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PROGNOSTIC SIGNIFICANCE OF PRE-TRANSPLANTATION FDG-PET/CT IN
PATIENTS WHO UNDERGO ALLOGENIC STEM CELL TRANSPLANTATION
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A positive scan in pre-transplantation fluorine-18 fluorodeoxyglu-
cose positron emission tomography (FDG-PET) has been shown to
be associated with a poor prognosis in patients with malignant lym-
phoma (ML) undergoing high-dose chemotherapy followed by au-
tologous stem cell transplantation (SCT). However, it remains
unclear with allogeneic SCT. Therefore, we conducted a retrospec-
tive analysis of 52 consecutive patients with ML who had undergone
FDG-PET scan before allogeneic SCT at our institution from Jan-
uary 2005 to July 2010. The median age was 52 years (range: 20-64),
and the median follow-up after allogeneic SCT was 475 days (range:
46-1553). Twenty-three patients were FDG-PET-negative and
twenty-nine were positive with a median SUV of 7.23 (range: 2.7-
17.82). Nine indolent lymphomas and 14 aggressive lymphomas
were PET-negative, while 14 indolent and 15 aggressive lymphomas
were PET-positive (p5 0.52). Among the PET-negative patients, 5
and 18 received myeloablative and reduced-intensity conditioning
respectively. On the other hand, 9 of the 20 PET-positive patients
received myeloablative conditioning (p 5 0.54). Other characteris-
tics (age, serum LDH, extranodal sites, donor source) were not sig-
nificantly different between the PET-positive and PET-negative
groups. Although the cumulative incidence of progression at 1 year
was lower in the PET-negative patients, there was no statistical sig-
nificance (15% vs 31%, p5 0.35). Although overall survival (OS) and
progression-free survival (PFS) rate at 3 years after allogeneic SCT
were higher in the PET-negative patients, there were no statistical
significances (OS 83% vs 58%, p 5 0.21; PFS 67% vs 53%, p 5
0.22). Median survival time was not reached in either PET-negative
or -positive patients.A multivariate analysis by Cox regression anal-
ysis showed that high serum LDH was associated with an increased
risk of poor OS (HR 4.11, 95% CI 1.23-13.78, p 5 0.02). On the
other hands, a positive PET findings did not significantly affect
the OS (HR 1.80, 95% CI: 0.46-6.96, p 5 0.40). In conclusion,
ours study suggested that, in contrast to the setting of autologous
SCT, a positive pre-transplant PET finding may not be a predictor
of poor OS in patients with lymphoma who underwent allogeneic
SCT.270
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN LYMPHOMA
PATIENTS: THE IRANIAN EXPERIENCE
Alimoghaddam, K., Jahani, M., Mousavi, S.A., Bahar, B., Iravani, M.,
Hamidieh, A.A., Jorjani, H., Jalali, A., Ghavamzadeh, A. Tehran
University of Medical Sciences, Tehran, Tehran, Islamic Republic of Iran
Background: Autologous hematopoietic stem cell transplantation
(HSCT) is a potentially curative treatment in patients with lym-
phoma including Hodgkin’s disease (HD) and non-Hodgkin’s lym-
phoma (NHL).
Patients and Methods: 416 lymphoma patients (269 male and 147
female) with a median age of 25 years (range: 12-60 years) in 204HD
patients and amedian age of 33 years (range: 8-62 years) in 206NHL
Patients had received HSCT in our center from January, 1992
through October, 2010. The most common subtypes of NHL Pa-
tients were 86 (42%) diffuse large B-cell lymphoma and 35 (17%)
lymphoblastic lymphoma. The most common status of disease be-
fore transplantation was First and second complete remission in
NHL patients and second complete remission in HD patients.
The sources of hematopoietic stem cells for lymphoma patients
were 397 peripheral blood (194 NHL, 203 HD), 16 bone marrow(10 NHL, 6 HD) and 3 patients with combined Peripheral blood
and bone marrow (2 NHL, 1 HD).
Results:Themedian time (days) to AbsoluteNeutrophil Count.5
0.5 * 109/L was114 in HD and113 in NHL patients. The median
time (days) to platelet count.5 20 * 109/L was122 inHD and118
in NHL patients. The median follow up time was 14 months. The
three years, disease-free survival (DFS) for HD and NHL patients
was 78.8% and 63.3%, recpectively. The three years overall survival
(OS) for HD and NHL patients was 91.8% and 71.4 %. Acute and
chronic GVHD occurred in 16 (53.3%) and 7 (23.3%) of NHL
patients with Allogeneic HSCT. The three years, DFS for autolo-
gous and allogeneic transplantation in NHL patients was 64.9%
and 56.3% (p 5 0.543).The three years, OS for autologous and
allogeneic transplantation in NHL patients was 72.2% and 68.5
%, (p 5 0.843).
Conclusion:Our results confirm that autologousHSCT is a suitable
treatment in patients with NHL and relapsed HD. More impor-
tantly, there is no significant difference between autologous and
allogeneic HSCT in NHL patients.271
AUTOLOGOUS STEM CELL TRANSPLANTATION AS FRONT LINE THERAPY
DOES NOT IMPROVE THE OUTCOME OF HIGH RISK AGGRESSIVE NON-
HODGKIN’S LYMPHOMA: A SINGLE CENTER STUDY
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Background:The role of high dose therapy (HDT) followed by au-
tologous stem cell transplantation (ASCT) as front-line therapy in
the high risk aggressive non-Hodgkin’s lymphoma (NHL) patients
is still a matter of debate, but several studies demonstrated the effi-
cacy of HDT. Since Rituximab added to CHOP chemotherapy,
OS and PFS were significantly improved. Therefore, we analysed
to compare conventional chemotherapy with HDT followed by
ASCT in aggressive NHL.
Patients andMethods:We retrospectively reviewed themedical re-
cords of 357 patients with primary diagnosed aggressive NHL from
January 2002 to December 2009. Among them, we select patients
who achieved to complete or partial remission after first induction
chemotherapy or had $ 3 International Prognostic Index (IPI)
scores or stage III, IV. Among 357 patients, 42 patients younger
than 65 years were enrolled and categorized to two groups: conven-
tional chemotherapy group (n 5 33, 79%) and HDT followed by
ASTC group (n 5 9, 21%).
Results: The median age at the time of diagnosis was 46 years
(range, 15-64). Diffuse large B-Cell lymphoma (DLBLC, 48%),
T-cell lymphoma (38%), lymphoblastic lymphoma (7%) was in-
cluded. The proportion of Rituximab including regimen for induc-
tion chemotherapy were 49%. The five-year overall survival rate
was not significantly different between two groups (72% in chemo-
therapy group vs. 70% in HDT group, P5 0.73). And the estimated
progression free survival at five years was not significantly different
between two groups (51% in chemotherapy group vs. 53% in
HDT group, P 5 0.63).
Conclusion: The efficacy of HDT followed by ASTC during first-
line treatment in patients with aggressiveNHLdoes not improve the
outcome and should be evaluated in randomized trials.272
TRANSPLANT OUTCOMES IN MULTIPLE MYELOMA PATIENTS YOUNGER
VERSUS OLDER THAN 60 YEARS OF AGE IN THE ERA OF NEWER
TARGETED AGENTS
Naik, S., Shope, D., Albright, C., Graham, R., Levitan, D., Zamkoff, K.,
D’Agostino R Jr., Jr., Hurd, D. Wake Forest Hospital Medical Center,
Winston-Salem, NC
Introduction: Various newer agents are available recently and revo-
lutionized treatment ofmyeloma and are usedwith intention to over-
come the adverse influence of cytogenetic abnormalities. We were
Poster Session I S253interested in younger versus older patients(pts) for any difference in
disease characteristics and clinical outcome in the era of newer
agents.
Patients: We retrospectively analyzed 122 consecutive pts
(M77:F55) who underwent ASCT for multiple myeloma between
February, 2005 and July 2010, after newer agents were introduced.
Median age was 58 years (38-76). The median length of follow-up
was 1.1 year (33-1833days) after the initial transplant date.
Patient characteristics: High risk cytogenetics was seen in 40%
(n 5 29) of patients younger than 60 years of age compared to
28% (n5 14) of the pts in older group. Either deletion 13 or 17 de-
letion was similar in both groups 20% (n5 15) in younger and 22%
(n5 11) in older group. Trisomy 11 was more commonly seen in the
younger patients 11% (n 5 8) vs. 0%. Prior MGUS or smoldering
myeloma was more common in older pts (16%; n 5 8) vs. (7%;
n 5 5). Plasmacytomas (PCM) as presenting symptom was more
common 24% (n 5 17) in younger patients compared to 16%
(n 5 8) older pts.
Table 1. Patient characteristics of multiple myeloma patients
younger and older than 60 years of age
Age in years <60 (n572) >60 (n550)M:F 44 : 28 29 : 21
Disease prior to myeloma
Light chain disease 0 (0%) 2 (4%)
MGUS/smoldering MM 5 (7%) 8(16%)
Plasmacytoma 17 (24%) 8 (16%)
Amyloid 1 (1%) 3 (6%)
Plasma cell leukemia 0 (0%) 1 (2%)
De novo myeloma 49 (68%) 28 (56%)
WHO/ISS
albumin 3.6 (2.1-4.6) 3.6 (2.0-4.6)
Beta2 microglobulin 2.7 (1.4-34) 3.6 (1.3-15)
I 32 (44%) 12 (24%)
II 14 (19%) 22 (44%)
III 24 (33%) 12 (24%)
Not calculated 2(3%) 4 (8%)
Durie-Salmon staging
I 9 (12%) 9 (18%)
II 14 (19%) 17 (34%)
III 49 (68%) 24 (48%)
Cytogenetic abnormalities
13 del/17 del 15 (20%) 11 (22%)
Trisomy 11 8 (11%) 0 (0%)
T(11:14) 1 (1%) 3 (6%)
complex 5 (7%) 1 (2%)
aneuploidy 0 (0%) 1 (2%)
Pretransplant treatments
VAD/DVD 9 (12%) 9 (18%)
Melphalan 4 (7%) 4 (8%)
Thalidomide 18 (25%) 16 (32%)
Lenalidomide 14 (19%) 9 (18%)
Bortezomib 17 (24%) 12 (24%)
Post transplant treatments
Thalidomide 2 (3%) 2 (4%)
Lenalidomide 37 (51%) 29 (58%)
No maintenance 27 (38%) 18 (36%)
Second transplants 2 (3%) 1 (2%)Methods: Various pretransplant characteristics including cytoge-
netics and free light chain ratios were evaluated for remission status
and impact on progression.
Results: Majority of younger pts (44%; n 5 32) had stage I disease
by ISS staging compared to older pts with stage II disease (44%; n5
22). By Durie-Salmon staging majority had stage III disease; 68% of
younger (n5 49) compared to 48% of older pts (n5 24). The 3 year
overall survival was 71% for pts over 50 years of age compared to
40.2% for pts younger than 50 years of age (p5 0.065).Median sur-
vival was 927 days for patients younger than 50 years of age, but not
reached for pts older than 50 years. Three patterns of relapses were
seen: Bone marrow (BM) relapse; free light chains (FLC); plasmacy-toma only recurrence.None of the pts with FLC only relapse died of
relapse.
Conclusion:The younger patients have more aggressive clinical
presentation compared to older myeloma patients. Pre and post
transplant strategies need to be better defined to improve out-
come of younger myeloma patients with aggressive clinical
course.273
COMBINED EPIGENETIC AND IMMUNE-BASED THERAPIES FOR RE-
LAPSED HODGKIN’S LYMPHOMA POST HEMATOPOIETIC STEM CELL
TRANSPLANT
Cruz, C.R.Y.1, Gerdemann, U.1, Shaffer, J.A.1, Leen, A.M.1,
Rooney, C.M.1, Younes, A.2, Horton, T.M.3, Heslop, H.E.1,
Bollard, C.M.1 1Baylor College ofMedicine/TheMethodist Hospital/Texas
Children’s Hospital, Houston, TX; 2Baylor College of Medicine, Houston,
TX; 3University of Texas MD Anderson Cancer Center, Houston, TX
Hematopoietic stem cell transplant (HSCT) remains the pri-
mary therapy for Hodgkin’s Lymphoma (HL) patients who re-
lapse following standard therapies. Those who relapse have
limited options for long-term cure. Two approaches have recently
shown promise: T cell therapy, and therapy with epigenetic-mod-
ifying drugs. As usually seen in cancer, a multimodality approach
may work best: we thus hypothesize that a combined immune–
based and epigenetic therapy, targeting our antigen of choice MA-
GEA4, will be an effective approach for treating relapsed HL post
HSCT.
Success in T cell therapy targeting Epstein Barr virus (EBV) pro-
teins in lymphoma is limited because most are EBV negative. MA-
GEA4 is expressed in EBV-negative HL, seen only in tumor &
immune-privileged germ cells, and immunogenic. We also observed
that we can increaseMAGE expression by epigenetic modification of
the tumor, supporting our hypothesis.
To verify whether MAGE T cells can be expanded from different
donors, cells from HL patients (n5 4), healthy donors (n5 15) and
cord blood (n 5 4) were stimulated weekly with autologous DCs
pulsed with MAGEA4 peptides. We generated a mixed population
of activated T cells with specificity against MAGE from all donor
types. These cells recognized different MAGE epitopes, and evalu-
able T cells demonstrated specific killing against autologous targets
and HLA-matched HL cell lines.
To explore the effect of combiningMAGET cells with the epige-
netic drug decitabine, we first looked at the effects of adding the drug
to our T cells – to ensure that the drug does not negatively affect
them. We saw no overt effects on or changes in phenotype or spec-
ificity when MAGEA4 T cells were cultured with decitabine. We
then confirmed that treatment of tumors with decitabine in vitro
increased MAGE expression using qPCR.
Lastly, we tested our prediction that increases in the frequency
of MAGEA4 specific T cells would be seen in HL patients receiv-
ing decitabine as therapy. We saw increased MAGEA4 specific T
cells in HL patients following treatment (likely reflecting increased
antigens in vivo) – manifested as an increase in the epitope reper-
toire and in the number of IFNg-secreting cells. We were unable
to expand MAGE T cells in all HL patients treated with decita-
bine, however, highlighting the need for adoptive transfer of these
cells.
These suggest that MAGEA4-specific T cell immunotherapy,
along with epigenetic therapy, is a practical approach for treatment
of relapsed HL post-HSCT.274
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR MULTIPLE
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ACTIVE ANTIRETROVIRAL THERAPY (HAART) ERA
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